{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Infectious Complications of Newer Agents in the Fight Against Diabetes

Activity Steps

Purpose of Activity

To provide information about infectious complications associated with three newer antidiabetic medication classes that include GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe the prevalence and complications of diabetes in the US and the mechanism of action for each of the three newer antidiabetic medication classes.
  2. Identify infectious complications associated with use of GLP-1 RAs, SGLT2 inhibitors, and DPP-4 inhibitors.
  3. Summarize diabetes treatment recommendations for the newer antidiabetic medication classes.
Price: $17.95

Credits:

  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Awarded Advanced Pharmacology Hours







Test Code: NP1120B
Published: Nov 2020
Expires: 12/6/2024
Required Passing Score: 16/20 (80%)
Authors: Kayla R. Stover, PharmD; Emily Hugh, PharmD; Justin J. Sherman, PharmD, MCS; Scott S. Malinowski, PharmD; Gideon J. Berdahl, PharmD; Daniel M. Riche, PharmD